About usSign in

Aquilo Capital Management

Status
ACTIVE
Global HQ
San Francisco, United Statess
Countries of investment
  • USA: California
  • Massachusetts
  • Connecticut
  • New Jersey
  • Belgium:East Flanders
  • Denmark: Copenhagen
Investment stages
  • Seed
  • Series A
Industries
  • Health Tech
  • BioTechnology
  • Artificial Intelligence
  • Data Science
About
Aquilo Capital Management invests in biotech companies using cuttingedge science to tackle urgent medical challenges, aiming for significant returns and transformative impact on healthcare.
Min check size
$1M
Max check size
$3M
Fund size
NPS

Investment Thesis

Aquilo Capital invests in drug development companies that harness the poTheyr of cuttingedge science to address urgent medical needs.
Lead investor
Co Invest
Number of exits
Preferred contact method

Team

Marc Schneidman Chief Investment Officer

Adam Bristol

PhD Managing Director

Head of Investments

Patrick Rivers Managing Director

Head of Research

Katerina Popova

PhD Vice President

Senior Research Analyst

Christian Sirko Vice President

Senior Research Analyst

Portfolio

Arrowhead Pharmaceuticals

Argenx

Blueprint Medicines

Loxo Oncology

Dicerna Pharmaceuticals

Genmab

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp